DayTwo Science Cited in 10-Year $150 Million NIH Precision Nutrition Strategic Plan

DayTwo, the pioneer of metabolic disease remission for diabetes, prediabetes, clinical obesity and NASH, today announced that its foundational science has been cited as a key component in the National Institutes of Health $150 Million 2020-2030 Strategic Plan. This research identified the ability to predict blood sugar responses to food based using machine learning algorithms based on high resolution, gut microbiome profiling and additional clinical and personal parameters.

The NIH Strategic plan focuses on “Precision Nutrition—What to Eat to Stay Healthy.” NIH in conjunction with the Nutrition Research Task Force will partner with private and public organizations in order to accelerate nutrition science with the focus on precision medicine. The ambitious initiative looks to push forward the concept of individualized dietary recommendations in order to maximize health as well as prevent and combat disease.

Click here to see the 1 minute video excerpt from the NIH announcement.

“We are thrilled to be recognized by NIH as a pioneer in the field of precision nutrition.  We look forward to supporting and participating in the ongoing research effort toward new discoveries” said Lihi Segal, CEO and Founder of DayTwo.

Metabolic disease (diabetes, prediabetes, clinical obesity and NASH) impacts almost 3/4 of US adults and costs the US economy almost $700 billion a year.  In the era of COVID-19, people with diabetes are #1 and #2 at risk for hospitalizations and death if they contract the disease.  Poor nutrition is a root cause of metabolic disease and according to the ADA food choices are the greatest stressor and have the greatest impact on daily life for people with diabetes.

DayTwo was founded as a result of a clinical trial published in Cell in 2015 entitled Personalized Nutrition by Prediction of Glycemic Responses.  A follow up clinical trial was published in JAMA in 2019 entitled Assessment of a Personalized Approach to Predicting Postprandial Glycemic Responses to Food.  Both studies demonstrated that people respond differently to the same food, and the personalized response can be predicted using machine learning algorithms based on high resolution, gut microbiome profiling and additional clinical and personal parameters.

Employers and payors looking to learn more can contact Robert Boyer VP of Enterprise Solutions at Robert.Boyer@DayTwo.com.

About DayTwo

DayTwo is the only precision nutrition solution that enables a path to remission for metabolic disease.  DayTwo’s telehealth-centric, high touch / high tech solution employs machine learning algorithms based high resolution gut microbiome profiling and additional clinical and personal parameters, a care team of Certified Diabetes Care and Educational Specialists / Registered Dietitian Nutritionists skilled in behavioral coaching and a digital app to achieve outcomes.  DayTwo offers up to 100% fees at risk for its solution.

For questions or comments about this release please contact Andrew.Federici@DayTwo.com 415-426-4767.



Related Posts